LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Free Cash Flow
-$19.6m
CAGR 3-Years
13%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Free Cash Flow
$52.6m
CAGR 3-Years
27%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Free Cash Flow
-€49.4m
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
-7%
Uniqure NV
NASDAQ:QURE
Free Cash Flow
-$153.6m
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Free Cash Flow
-$151m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Free Cash Flow
-$317.9m
CAGR 3-Years
-27%
CAGR 5-Years
-33%
CAGR 10-Years
-29%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Free Cash Flow?
Free Cash Flow
-19.6m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Free Cash Flow amounts to -19.6m USD.

What is LAVA Therapeutics NV's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-16%

Over the last year, the Free Cash Flow growth was 52%. The average annual Free Cash Flow growth rates for LAVA Therapeutics NV have been 13% over the past three years , -16% over the past five years .

Back to Top